These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial. DeVore AD; Mi X; Thomas L; Sharma PP; Albert NM; Butler J; Hernandez AF; Patterson JH; Spertus JA; Williams FB; Duffy CI; McCague K; Fonarow GC J Am Heart Assoc; 2018 Jun; 7(12):. PubMed ID: 29895587 [TBL] [Abstract][Full Text] [Related]
29. Effect of the angiotensin-receptor-neprilysin inhibitor in heart failure patients with left ventricular ejection fraction higher than 40. Zhao M; Xin Y; Li J; Cao X; Liu X Medicine (Baltimore); 2019 Sep; 98(39):e17296. PubMed ID: 31574852 [TBL] [Abstract][Full Text] [Related]
30. Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review. Proudfoot C; Studer R; Rajput T; Jindal R; Agrawal R; Corda S; Senni M Int J Cardiol; 2021 May; 331():164-171. PubMed ID: 33545266 [TBL] [Abstract][Full Text] [Related]
31. Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study. Ganesananthan S; Shah N; Shah P; Elsayed H; Phillips J; Parkes A; Morgan A; Yousef Z Open Heart; 2020 Oct; 7(2):. PubMed ID: 33020255 [TBL] [Abstract][Full Text] [Related]
33. Sacubitril/valsartan for heart failure with reduced left ventricular ejection fraction : A retrospective cohort study. De Vecchis R; Ariano C; Di Biase G; Noutsias M Herz; 2019 Aug; 44(5):425-432. PubMed ID: 29350254 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of Patients with Heart Failure to Determine Eligibility for Treatment with Sacubitril/Valsartan: Insights from a Veterans Administration Healthcare System. Han J; Chung F; Nguyen QL; Mody FV; Jackevicius CA Pharmacotherapy; 2019 Nov; 39(11):1053-1059. PubMed ID: 31498903 [TBL] [Abstract][Full Text] [Related]
35. Sacubitril/valsartan in heart failure with reduced ejection fraction patients: Real world experience on advanced chronic kidney disease, hypotension, and dose escalation. Chang HY; Feng AN; Fong MC; Hsueh CW; Lai WT; Huang KC; Chong E; Chen CN; Chang HC; Yin WH J Cardiol; 2019 Oct; 74(4):372-380. PubMed ID: 30982680 [TBL] [Abstract][Full Text] [Related]
36. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland. Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956 [TBL] [Abstract][Full Text] [Related]
37. Cost-Effectiveness Analysis of Sacubitril/Valsartan for the Treatment of Heart Failure with Reduced Ejection Fraction in the United States. Zueger PM; Kumar VM; Harrington RL; Rigoni GC; Atwood A; DiDomenico RJ; Touchette DR Pharmacotherapy; 2018 May; 38(5):520-530. PubMed ID: 29601093 [TBL] [Abstract][Full Text] [Related]
38. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936 [TBL] [Abstract][Full Text] [Related]
39. Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives. Yandrapalli S; Andries G; Biswas M; Khera S Vasc Health Risk Manag; 2017; 13():369-382. PubMed ID: 29042791 [TBL] [Abstract][Full Text] [Related]